Breaking the Glass Ceiling: Low eGFR in the Use of MRA Therapy

Kevin Damman; Jeffrey Testani

doi:10.1016/j.jchf.2022.08.017

Breaking the Glass Ceiling: Low eGFR in the Use of MRA Therapy

Kevin Damman^*
, Jeffrey Testani

^*Corresponding author for this work

Cardiovascular Centre (CVC)

Research output: Contribution to journal › Editorial › Academic › peer-review

80 Downloads (Pure)

Original language	English
Pages (from-to)	871-873
Number of pages	3
Journal	JACC: Heart Failure
Volume	10
Issue number	11
DOIs	https://doi.org/10.1016/j.jchf.2022.08.017
Publication status	Published - Nov-2022

Keywords

chronic kidney disease
finerenone
heart failure
type 2 diabetes

Access to Document

10.1016/j.jchf.2022.08.017

Breaking the Glass CeilingFinal publisher's version, 444 KBLicence: Taverne

Handle.net

Persistent link

Cite this

@article{7cc628aa687940dc98c476e9fb3368b7,

title = "Breaking the Glass Ceiling: Low eGFR in the Use of MRA Therapy",

keywords = "chronic kidney disease, finerenone, heart failure, type 2 diabetes",

author = "Kevin Damman and Jeffrey Testani",

year = "2022",

month = nov,

doi = "10.1016/j.jchf.2022.08.017",

language = "English",

volume = "10",

pages = "871--873",

journal = "JACC: Heart Failure",

issn = "2213-1779",

publisher = "ELSEVIER SCI LTD",

number = "11",

}

TY - JOUR

T1 - Breaking the Glass Ceiling

T2 - Low eGFR in the Use of MRA Therapy

AU - Damman, Kevin

AU - Testani, Jeffrey

PY - 2022/11

Y1 - 2022/11

KW - chronic kidney disease

KW - finerenone

KW - heart failure

KW - type 2 diabetes

U2 - 10.1016/j.jchf.2022.08.017

DO - 10.1016/j.jchf.2022.08.017

M3 - Editorial

AN - SCOPUS:85140236356

SN - 2213-1779

VL - 10

SP - 871

EP - 873

JO - JACC: Heart Failure

JF - JACC: Heart Failure

IS - 11

ER -